Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Kennelly

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Age and Ageing|January 23, 2019
A Hospital Wide Point Prevalence of Adult Urinary Incontinence and Audit of Continence CarePatricia Harkins, Helen O'Brien, Deirdre McCartan, et al.
Irish Journal of Psychological Medicine|May 29, 2020
Developing a guidance resource for managing delirium in patients with COVID-19David Meagher, Dimitrios Adamis, Suzanne Timmons, et al.
Frontiers in Neurology|March 27, 2020
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD TrialLaila Abdullah, Fiona Crawford, Magda Tsolaki, et al.
Journal of the Neurological Sciences|July 23, 2013
Frequent inaccuracies in ABCD2 scoring in non-stroke specialists' referrals to a daily Rapid Access Stroke Prevention serviceDavid Bradley, Simon Cronin, Justin A Kinsella, et al.
Lancet (London, England)|May 17, 2025
Regulatory asymmetry in Alzheimer's disease careJuan Fortea, Marina Boban, Sebastiaan Engelborghs, et al.
BMJ Open|October 11, 2014
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's diseaseBrian Lawlor, Sean Kennelly, Sarah O'Dwyer, et al.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Age and Ageing|January 23, 2019
A Hospital Wide Point Prevalence of Adult Urinary Incontinence and Audit of Continence CarePatricia Harkins, Helen O'Brien, Deirdre McCartan, et al.
Irish Journal of Psychological Medicine|May 29, 2020
Developing a guidance resource for managing delirium in patients with COVID-19David Meagher, Dimitrios Adamis, Suzanne Timmons, et al.
Frontiers in Neurology|March 27, 2020
The Influence of Baseline Alzheimer's Disease Severity on Cognitive Decline and CSF Biomarkers in the NILVAD TrialLaila Abdullah, Fiona Crawford, Magda Tsolaki, et al.
Journal of the Neurological Sciences|July 23, 2013
Frequent inaccuracies in ABCD2 scoring in non-stroke specialists' referrals to a daily Rapid Access Stroke Prevention serviceDavid Bradley, Simon Cronin, Justin A Kinsella, et al.
Lancet (London, England)|May 17, 2025
Regulatory asymmetry in Alzheimer's disease careJuan Fortea, Marina Boban, Sebastiaan Engelborghs, et al.
BMJ Open|October 11, 2014
NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's diseaseBrian Lawlor, Sean Kennelly, Sarah O'Dwyer, et al.
BMJ Open|July 21, 2016
European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flowOlga Meulenbroek, Sarah O'Dwyer, Daan de Jong, et al.
Plos Medicine|September 25, 2018
Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trialBrian Lawlor, Ricardo Segurado, Sean Kennelly, et al.
Research Square|January 19, 2022
The risk of COVID-19 death is much greater and age-dependent with type I IFN autoantibodiesJeremy Manry, Paul Bastard, Adrian Gervais, et al.
Pageof 3